Bio-Rad 10-Q Details Q3: $458.6M GAAP Profit Is a Sartorius Mark; Operations Lost $49.7M
BIO sits 60% above its 52-week low of $236.73.
Summary
Bio-Rad's Q3 GAAP profit of $458.6 million was almost entirely a non-cash Sartorius mark-to-market gain; core operations lost $49.7 million after $77.2 million of restructuring and a $49.8 million Celsee impairment, on flat sales of $656.4 million.
Key Events · Earnings and Guidance · BIO
-
Q3 Sales Flat at $656.4M
Net sales rose 0.5% reported and 0.7% currency-neutral versus $653.0 million. Clinical Diagnostics grew 2.7% to $401.8 million while Life Science fell 2.8% to $254.6 million.
-
GAAP Profit Is a Sartorius Mark
GAAP net income of $458.6 million ($17.02 per diluted share) came from a $588.2 million non-cash gain on equity securities. GAAP operations lost $(49.7) million after $77.2 million of restructuring and a $49.8 million intangible impairment.
-
July Restructuring Costs $77.6M in Q3
The July 2026 plan carries $80 million to $90 million of expected pre-tax cost and is targeted to cut annual operating expenses by $30 million to $35 million by the end of 2027, with completion expected by then.
-
Celsee Technology Written to Zero
Bio-Rad cut R&D and marketing on single-cell products from the 2020 Celsee deal and recorded a $49.8 million impairment in the Life Science segment, reducing the developed technology's carrying value to zero.
Analysis · BIO · Industrial Applications And Services
The headline profit is accounting, not operations. Bio-Rad's $458.6 million of Q3 GAAP net income rests on a $588.2 million non-cash gain from marking up its Sartorius stake — a paper entry that reverses with the share price and involves no cash. Strip that out and the core business lost $(49.7) million from operations after $77.2 million of restructuring charges and a $49.8 million write-off of the Celsee single-cell technology, which the company has effectively abandoned. Sales were essentially flat at $656.4 million, with Clinical Diagnostics up 2.7% offsetting a 2.8% decline in Life Science. The offsetting item is the July 2026 restructuring: $80-90 million of total cost for $30-35 million of annual savings by the end of 2027, a real margin lever but one that keeps charges flowing through 2027. Cash generation slipped to $303.2 million for nine months from $367.3 million, and the $400 million of 3.3% notes now sit in current liabilities ahead of their March 2027 maturity — comfortably covered by $1.66 billion of cash and short-term investments.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIO was trading at $379.29 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $236.73 to $396.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.